AbbVie’s migraine drug meets main goal of late-stage study

(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage trial.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)